Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Vaxcyte (PCVX), a clinical-stage vaccine innovation company, has scheduled its fourth quarter and full year 2024 financial results announcement for February 25, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT on the same day, where management will discuss financial results and provide a business update. Investors can join the call by dialing 800-225-9448 (domestic) or 203-518-9708 (international) with conference ID PCVXQ424. A live webcast will be available on Vaxcyte's website and will remain archived for 30 days after the event.
Vaxcyte (PCVX), una società innovativa nel settore dei vaccini in fase clinica, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 25 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET / 13:30 PT nello stesso giorno, durante il quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento aziendale. Gli investitori possono partecipare alla chiamata componendo il numero 800-225-9448 (nazionale) o 203-518-9708 (internazionale) con l'ID conferenza PCVXQ424. Un webcast dal vivo sarà disponibile sul sito web di Vaxcyte e rimarrà archiviato per 30 giorni dopo l'evento.
Vaxcyte (PCVX), una empresa innovadora en vacunas en etapa clínica, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 25 de febrero de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia y un webcast a las 4:30 p.m. ET / 1:30 p.m. PT el mismo día, donde la dirección discutirá los resultados financieros y proporcionará una actualización del negocio. Los inversores pueden unirse a la llamada marcando el 800-225-9448 (nacional) o el 203-518-9708 (internacional) con el ID de conferencia PCVXQ424. Un webcast en vivo estará disponible en el sitio web de Vaxcyte y permanecerá archivado durante 30 días después del evento.
Vaxcyte (PCVX)는 임상 단계의 백신 혁신 회사로, 2025년 2월 25일에 2024년 4분기 및 연간 재무 결과 발표를 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분 ET / 오후 1시 30분 PT에 컨퍼런스 콜과 웹캐스트를 개최하여 경영진이 재무 결과를 논의하고 비즈니스 업데이트를 제공할 것입니다. 투자자들은 800-225-9448(국내) 또는 203-518-9708(국제)로 전화하여 PCVXQ424 컨퍼런스 ID로 콜에 참여할 수 있습니다. Vaxcyte의 웹사이트에서 실시간 웹캐스트가 제공되며, 이벤트 후 30일 동안 아카이브로 남아 있을 것입니다.
Vaxcyte (PCVX), une entreprise innovante dans le domaine des vaccins en phase clinique, a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 25 février 2025, après la clôture du marché. L'entreprise organisera une conférence téléphonique et un webcast le même jour à 16h30 ET / 13h30 PT, où la direction discutera des résultats financiers et fournira une mise à jour sur l'entreprise. Les investisseurs peuvent rejoindre l'appel en composant le 800-225-9448 (national) ou le 203-518-9708 (international) avec l'ID de conférence PCVXQ424. Un webcast en direct sera disponible sur le site de Vaxcyte et restera archivé pendant 30 jours après l'événement.
Vaxcyte (PCVX), ein innovatives Unternehmen im Bereich Impfstoffe in der klinischen Phase, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 für den 25. Februar 2025 nach Marktschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 13:30 Uhr PT eine Telefonkonferenz und einen Webcast veranstalten, in dem das Management die finanziellen Ergebnisse erörtert und ein Update zum Geschäft gibt. Investoren können an dem Anruf teilnehmen, indem sie 800-225-9448 (inland) oder 203-518-9708 (international) mit der Konferenz-ID PCVXQ424 wählen. Ein Live-Webcast wird auf der Website von Vaxcyte verfügbar sein und 30 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast of the conference call will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com. After the live webcast, the event will remain archived on Vaxcyte’s website for 30 days.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Communications
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
When will Vaxcyte (PCVX) release its Q4 and full year 2024 earnings?
What time is Vaxcyte's (PCVX) Q4 2024 earnings call?
How can investors access Vaxcyte's (PCVX) Q4 2024 earnings call?
How long will Vaxcyte's (PCVX) Q4 2024 earnings webcast be available?
